Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APEH | P13798 | 1/20 | 0.31 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468054 | 0.80 | RAPGEF4 (0.44) | RAPGEF4DDR1HTR6ELAVL1 | |
| SCHEMBL16541861 | 0.80 | RAPGEF4 (0.41) | RAPGEF4DDR1HTR6ELAVL1 | |
| Hydrochloric Acid SCHEMBL16528866 | 0.78 | RAPGEF4 (0.40) | RAPGEF4DDR1HTR6ELAVL1 | |
| SCHEMBL2461960 | 0.76 | DDR1 (0.35) | RAPGEF4DDR1 | |
| SCHEMBL27577523 | 0.76 | RAPGEF4 (0.53) | RAPGEF4HTR6KMT2AAPEHPPME1 | |
| SCHEMBL29179097 | 0.75 | RAPGEF4 (0.74) | RAPGEF4AGTR1KDM4E | |
| SCHEMBL29512049 | 0.72 | HTR6 (0.38) | RAPGEF4AGTR1HTR6APEHPPME1 | |
| SCHEMBL15155241 | 0.70 | HTR6 (0.39) | RAPGEF4DDR1HTR6ELAVL1APEH | |
| SCHEMBL16529666 | 0.69 | BRD9 (0.43) | DDR1KDM4E | |
| SCHEMBL27489684 | 0.69 | RAPGEF4 (0.44) | RAPGEF4DDR1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101212973-B | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility | ORGANON NV | 2011-11-16 | — | — | CN | disclosed |
| US-8022218-B2 | Hypogonadism; N-{3-[2-Bromo-4-(3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydro-quinolin-4-yl)-6-ethoxy-phenoxymethyl]-phenyl}-3,4,5-trimethoxy-benzamide; low molecular weight hormone mimetics; selective Follicle Stimulating Hormone receptor agonists | N.V. ORGANON (NL) | 2011-09-20 | — | — | US | disclosed |
| US-20080275042-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility | N.V. ORGANON (NL) | 2008-11-06 | — | — | US | disclosed |
| EP-1881830-B1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY | ORGANON NV (NL) | 2008-10-08 | — | — | EP | disclosed |
| CN-101212973-A | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility | ORGANON NV (NL) | 2008-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275042-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline Derivatives for the Treatment of Infertility | CATSPER1, ABCB11, ACR | RAPGEF4 3534/4885DDR1 3182/4885AGTR1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.